Direct intratumoral chemotherapy with carboplatin and epinephrine in a recurrent cervical chordoma: case report.
OBJECTIVE
Chordomas are rare primary bone tumors for which surgery is classically the first-line treatment. However, safe margins are often difficult to obtain, so that patients are at risk of local recurrence. Because radiation therapy and systemic chemotherapy show limited effectiveness, we report the use of direct intratumoral chemotherapy (IC) to treat recurrent chordoma.


METHODS
A 46-year-old man presented with a recurrent cervical chordoma after surgery and radiation therapy. This recurrence manifested as C4-C5 spinal cord compression.


METHODS
Three 22-gauge needles were inserted at the upper, middle, and lower parts of the tumor and advanced under computed tomographic guidance while injecting local anesthetic. A 5-mg/mL carboplatin solution was combined with epinephrine (to increase the concentration and antitumor effect of carboplatin) at a final concentration of 0.01 mg/mL and an iodinated contrast agent. We injected 3 to 5 mL of this solution over 5 minutes through each needle under computed tomographic guidance. Eleven intratumoral treatments were performed during an 18-month period.


CONCLUSIONS
A marked clinical response with regression of the spinal cord compression was observed, without specific toxicity. A good partial response was obtained with a 42% decrease in tumor volume (from 69 to 40 cm3). Moreover, the central part of the tumor showed tumor necrosis, as confirmed by histological examination. Thus, in patients with this rare tumor, intratumoral chemotherapy may be a valid treatment option when surgery and radiation therapy fail. Furthermore, intratumoral chemotherapy in combination with surgical treatment should be considered to improve the local control rate.
Guiu
Séverine
S
Department of Oncology, Georges-François Leclerc Anticancer Center, Dijon, France. Sguiu@dijon.fnclcc.fr
Guiu
Boris
B
Feutray
Sylvaine
S
Chauffert
Bruno
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002817:Chordoma / Q000175:diagnosis / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004837:Epinephrine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D013566:Sympathomimetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013566:Sympathomimetics; D016190:Carboplatin; D004837:Epinephrine